ArticleMedicine2026
Endothelial injury biomarker EASIX predicts mortality risk in adults with chronic obstructive pulmonary disease: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endothelial dysfunction has been implicated in the pathogenesis and progression of chronic obstructive pulmonary disease (COPD). This study aimed to examine the utility of the Endothelial Activation and Stress Index (EASIX), a novel biomarker of endothelial injury, for predicting mortality risk in US adults with COPD. Data from 1957 COPD participants in the 1999-2018 National Health and Nutrition Examination Survey were analyzed. EASIX was calculated from lactate dehydrogenase, serum creatinine, and platelet count. Multivariable Cox proportional hazard regression models were used to assess associations between log2-transformed EASIX tertiles (T1 lowest and T3 highest) and all-cause, cardiovascular disease (CVD), and chronic lower respiratory disease (CLRD) mortality by reporting hazard ratios and 95% confidence intervals. Over a median follow-up period of 79 months, 672 (27.70%) participants died, including 150 (22.32%) from CVD and 186 (27.68%) from CLRD. Compared to the T1 group, the hazard ratio (95% confidence intervals) for the T2 and T3 groups were 1.14 (0.85-1.53) and 2.42 (1.85-3.17), respectively, for all-cause mortality, 1.46 (0.90-2.38) and 3.02 (1.76-5.18), respectively, for CVD mortality, and 1.65 (1.00-2.71) and 2.56 (1.58-4.14), respectively, for CLRD mortality. Restricted cubic spline curves demonstrated a positive nonlinear relationship between log2-transformed EASIX and mortality risk. Subgroup analysis indicated the associations between log2-transformed EASIX and all-cause and CLRD mortality were more pronounced in patients with a history of CVD. EASIX independently predicts all-cause, CVD, and CLRD mortality in US individuals with COPD, supporting its potential utility for risk stratification and personalized management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.